Regeneron Pharmaceuticals (REGN) Long-Term Investments (2009 - 2026)

Regeneron Pharmaceuticals has reported Long-Term Investments for 18 years, with the latest figure at $9.8 billion in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Investments rose 5.49% year-over-year to $9.8 billion; the trailing twelve-month figure through Mar 2026 stood at $9.8 billion (up 5.49% YoY), and the FY2025 full-year result was $10.3 billion, up 15.29% from the prior year.
• Long-Term Investments for Q1 2026 stood at $9.8 billion, down from $10.3 billion in the prior quarter.
• The five-year high for Long-Term Investments was $10.3 billion in Q3 2025, with the low at $5.4 billion in Q4 2023.
• Average Long-Term Investments over 5 years is $7.7 billion, with a median of $7.1 billion recorded in 2022.
• Year-over-year, Long-Term Investments soared 99.9% in 2022 and slipped 18.13% in 2023.
• Tracing REGN's Long-Term Investments over 5 years: stood at $6.6 billion in 2022, then decreased by 18.13% to $5.4 billion in 2023, then jumped by 64.92% to $8.9 billion in 2024, then advanced by 15.29% to $10.3 billion in 2025, then decreased by 4.63% to $9.8 billion in 2026.
• The last three Long-Term Investments figures came in at $9.8 billion (Q1 2026), $10.3 billion (Q4 2025), and $10.3 billion (Q3 2025), per Business Quant data.

Peer Comparison